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Introduction
Annular elastolytic giant cell granuloma (AEGCG) 
was first described by O’Brien in 1975 and represents 
a rare granulomatous skin disease of undetermined 
cause [1]. Clinically it is characterized by annular 
plaques with raised erythematous borders, affecting 
predominantly sun-exposed skin (face, neck, 
upper extremities, anterior chest wall), [2]. Annular 
elastolytic giant cell granuloma usually presents in 
adults (age 40-70) and has a slight male predominance 
[3]. Histopathology shows infiltration of the upper 
and mid dermis by multinucleated giant cells, elastin 
degeneration, and elastophagocytosis [3].
Case Synopsis
A 38-year-old male, type II phototype, was observed 
in our dermatology department owing to a cutaneous 
frontal plaque, which displayed slow centrifugal 
growth for more than 1 year. He had previously been 
treated with topical and systemic antifungal agents, 
without improvement.
Dermatologic examination revealed an arciform 
erythematous plaque with sharply demarcated 
Abstract
Annular elastolytic giant cell granuloma (AEGCG) is 
a rare granulomatous skin disease of undetermined 
cause, characterized by annular plaques with raised 
erythematous borders in sun-exposed skin. The 
typical histologic features are dermal infiltration by 
multinucleated giant cells, elastin degeneration, and 
elastophagocytosis. The authors describe a clinical 
case of AEGCG, which exhibited an excellent response 
to hydroxycloroquine.
Figure 1. Clinical aspect of the lesions - frontal arciform erythematous plaque, with central atrophy.
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elevated borders, measuring 16cm x 5cm and 
occupying the upper half of the frontal region (Figure 
1). The center of the lesion exhibited clearing with 
slightly atrophic skin. The lesions were non-scaling 
and symptoms such as itching, tenderness, or pain 
were absent.
Annular erythematous plaques with the same 
characteristics were also present on the lateral 
cervical regions (two plaques on the right side, two 
on the left), the largest measuring 4cm (Figure 2). 
The latter lesions had appeared 2 months before 
observation.
The patient was a computer programmer and had no 
history of chronic sun exposure. There was no record 
of medical history, chronic disease, or medication.
All blood parameters were within normal values 
(hematological study, liver and renal function, lipid 
profile, glucose, serum angiotensin-converting 
enzyme levels, antinuclear antibody).
Histopathology demonstrated a granulomatous 
infiltrate in the superficial dermis, consisting of giant 
multinucleated cells (Figure 3a). Verhoeff van Gieson 
stain verified the degeneration of elastin fibers and 
elastophagocytosis (Figure 3b). No mucin deposition 
or altered collagen fibers were observed. A diagnosis 
of AEGCG was established and the patient was placed 
on sun protective measures and hydroxychloroquine 
400mg a day after ophthalmologic examination. No 
new lesions developed after initiation of treatment 
and a marked clearing of clinical lesions was observed 
after 3 months of therapy. Complete clearing of the 
lesions was observed after 6 months of treatment 
(Figure 4). Hydroxycloroquine was suspended and 
continuous sun protective measures recommended.
Case Discussion
Although the etiopathogenesis of AEGCG is still 
unclear, actinic damage is regarded as a trigger. 
O’Brien originally named this clinical entity “actinic 
granuloma” given what was thought to be the 
environmental origin of the cutaneous disease. 
According to this theory, elastic tissue damaged by 
actinic radiation acts as an antigenic trigger of an 
autoimmune reaction [1]. Although clinical lesions of 
AEGCG may present in other body areas, sun exposed 
skin is mainly affected. Supporting this theory is the 
fact that this disease is more frequently observed in 
lighter skin and in countries with higher UV index [4].
Figure 2. Clinical aspect of the lesions: lateral cervical annular 
erythematous plaques.
Figure 3. A) Upper dermis granulomatous infiltrates (H&E, 10x). B) Elastophagocytosis and degeneration of elastin fibers (Verhoeff van 
Gieson, 10x).
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Although our patient had a low phototype (type II) 
and resided in a sunny country, which can be regarded 
as two risk factors in the pathogenesis of the disease, 
no history of chronic outdoor activities was present. 
The authors question whether the chronic exposure 
to computer screens could have played some role in 
the etiology of our patient’s disease [5].
Conclusion
AEGCG has a slow, self-limited course, persisting 
many years before resolving [6]. Given the fact that 
lesions are often multiple and affect visible areas 
with consequent important cosmetic significance, 
therapy is of utmost importance in order to prevent 
the appearance of new lesions and the growth of 
established ones [6].
Treatment options are based on a small number 
of case reports, with different efficacy outcomes. 
Topical, intralesional, and systemic corticosteroids, 
hydroxycloroquine, cyclosporine, topical 
pimecrolimus, and sun protective measures are the 
most frequent therapeutic modalities used [6-9].
We report a clinical case of AEGCG with exuberant 
clinical presentation, which exhibited excellent 
response to hydroxycloroquine.
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Figure 4. Clinical aspect after treatment.
